Version of Record online: 9 MAY 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 48, Issue 2, pages 407–417, August 2008
How to Cite
Zeuzem, S., Yoshida, E. M., Benhamou, Y., Pianko, S., Bain, V. G., Shouval, D., Flisiak, R., Rehak, V., Grigorescu, M., Kaita, K., Cronin, P. W., Pulkstenis, E., Subramanian, G. M. and McHutchison, J. G. (2008), Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology, 48: 407–417. doi: 10.1002/hep.22403
This study is registered on ClinicalTrials.gov (identifier NCT00115908; http://clinicaltrials.gov/ct2/show/NCT00115908?term=human+genome+sciences&rank=2)
Potential conflict of interest: Dr. McHutchison is a consultant for and received grants from Anadys, Colsy Pharmaceutical Group, First Circle Medical, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals, Intarcia, Novartis, Pharmasset, Pfizer, Roche, Schering-Plough, Valeant Pharmaceuticals, Vertex Pharmaceuticals, and Wyeth. He received grants from Globe Immune, Medtronics, Salix Pharmaceuticals, and Sanofi-Aventis. He is also a consultant for Biolex, Epiphany Biosciences, InterMune Pharmaceuticals, National Genetics Institute, Peregrine, and United Therapeutics. Drs. Subramanian, Cronin and Pulkstenis own stock in Human Genome Sciences, Inc. Dr. Kaita is a consultant for, is on the speakers' bureau of, and received grants from Schering-Plough, Roche, and Gilead. Dr. Zeuzem is a consultant for, is on the speakers' bureau of, and received grants from Human Genome Sciences, Novartis, Roche, and Schering-Plough. Dr. Yoshida received grants from and advises Hoffmann-La Roche. He also received grants from Schering-Plough, GlaxoSmithKline, Ortho Janssen, Pfizer, Gilead Sciences, and Cangene. He advises Novartis. Dr. Benhamou is a consultant for and is on the speakers' bureau of Human Genome Science and Roche. Dr. Pianko is a consultant for, advises, and is on the speakers' bureau of Human Genome Sciences, Novartis, and Roche. Dr. Bain is a consultant for Human Genome Sciences. Dr. Shouval received grants from Human Genome Sciences. Dr. Flisiak received grants from Debiopharm. He advises and received grants from Human Genome Sciences and Roche.
- Issue online: 29 JUL 2008
- Version of Record online: 9 MAY 2008
- Accepted manuscript online: 9 MAY 2008 12:00AM EST
- Manuscript Accepted: 25 APR 2008
- Manuscript Received: 21 FEB 2008
- Human Genome Sciences Inc., Rockville, MD
- Novartis Pharma AG, Basel, Switzerland
- 14The SF-36 Health Survey (version 2.0) Technical Note. Boston, MA: Health Assessment Lab, September 20, 1996 (updates September 27, 1997)., .
- 15SF-36 Health Survey manual and interpretation guide. Boston, MA: New England Medical Center, The Health Institute, 1993., , , .